NYU Langone-Laura and Isaac Perlmutter Cancer Center, New York, NY
Vamsidhar Velcheti , Erika Klump , Andrew Long , Hadrian Green , Tessa Williams , Tielman Van Vleck , Hesper Wong , Randall Legg , Jon Apple , Bobby Arelli , Ilker Arslan
Background: Around 1.6 million patients in the US annually have a pulmonary nodule (PN) found on imaging. Previous studies suggest 1-12% of PNs represent an underlying malignancy at a potentially curative stage. PNs ≥6mm are considered higher risk. Despite guideline availability, only about one-third of commercially insured patients with a PN receive recommended workup, which may include further investigation via imaging or surgery. In addition, patients and providers may delay workup of PNs identified during COVID-19. We aimed to describe variations in PN workup for different patient demographic and clinical characteristics at 7 healthcare institutions in New York (NY) state. Methods: We used a retrospective cross-sectional design in which structured demographic and unstructured clinical data were used to analyze patient documents from a NY state health information exchange from January 2018 to February 2022. Clinical features were abstracted using a clinical natural language processing platform, CLiX unlock. Results: 58 million documents from 5.5 million unique patients were analyzed. Of the overall 151,436 patients with PNs, workup was found in 47% (71,071). Across institutions, workup ranged between 24% and 52%; 40% (60,749) had evidence of a PN in the upper lung location. We found 52,789 patients (35%) had a maximum PN ≥6mm and of those, 55% (28,958) had a workup (Table). For patients with a PN ≥6mm, workup for non-English speaking patients was 9% lower than for English speaking patients (47% vs 56%), 17% lower for patients 18-44 years than patients 45-90 years (39% vs 56%), 47% lower for patients presenting with a chest injury rather than cancer screening (28% vs 75%), and 9% higher for patients with initial imaging via chest computed tomography (CT) rather than other CT (58% vs 49%). After the start of the COVID-19 pandemic (January 2020), overall workup decreased 3.8% and prevalence of symptoms such as dyspnea and chest pain increased. Conclusions: The descriptive findings of this analysis demonstrate gaps and variations in workup for patients with PNs across different demographics and clinical scenarios. A subsequent project is underway to explore strategies for improvement in adherence to guideline-recommended care to benefit patients by diagnosing lung cancer at an earlier, potentially curative stage.
Characteristic | Group | Total Patients w/ PNs | Patients w/ Workup n (%) | Total Patients w/ PNs ≥6mm | Patients w/ Workup PNs ≥6mm n (%) |
---|---|---|---|---|---|
Age | 18-44 | 14,296 | 4,213 (30) | 4,059 | 1,571 (39) |
44-65 | 53,032 | 23,337 (44) | 15,925 | 8,343 (52) | |
65+ | 84,108 | 43,521 (52) | 32,805 | 19,044 (58) | |
Language | English | 112,409 | 54,033 (48) | 39,647 | 22,279 (56) |
Spanish | 8,990 | 3,389 (38) | 3,045 | 1,360 (45) | |
Chinese | 1,258 | 571 (45) | 546 | 269 (49) | |
Other | 4,227 | 1,995 (47) | 1,623 | 848 (52) | |
Index Imaging Type | CT chest | 105,037 | 52,503 (50) | 35,504 | 20,517 (58) |
CT, other | 37,899 | 14,925 (39) | 12,565 | 6,212 (49) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Annual Meeting
First Author: Bilja Kurian Sajith
2022 ASCO Annual Meeting
First Author: Bharat Nayar Nandakumar
2022 ASCO Annual Meeting
First Author: Aneesha Ananthula
2024 ASCO Annual Meeting
First Author: Erin Elizabeth Hahn